Cancer Genetics (CGIX) Tops Q3 EPS by 5c

Cancer Genetics (NASDAQ: CGIX) reported Q3 EPS of ($0.23), $0.05 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $6.93 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• BayCom Corp (BCML) Misses Q1 EPS by 4c
• P.A.M. Transportation Services (PTSI) Misses Q1 EPS by 9c
• Chemung Financial (CHMG) Tops Q1 EPS by 44c